BRISBANE, Calif., Nov. 08, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Dr. Peter Maag, Chief Executive Officer, and Charles Constanti, Chief Financial Officer, will be participating in four upcoming investor conferences:
Mizuho Global Investor Conference in New York City
- Dr. Peter Maag and Charles Constanti will participate in one-on-one meetings on Monday, November 14, 2016
7th Annual Craig-Hallum Alpha Select Conference in New York City
- Dr. Peter Maag and Charles Constanti will present on Wednesday, November 16, 2016 at 11:50am PT/2:50pm ET.
28th Annual Piper Jaffray Healthcare Conference in New York City
- Dr. Peter Maag and Charles Constanti will present on Tuesday, November 29, 2016 at 11:00am PT/1:00pm ET.
Evercore ISI MedTools Investor Conference in Boston, MA
- Dr. Peter Maag and Charles Constanti will participate in one-on-one meetings on December 1, 2016.
A live audio webcast of the Craig-Hallum Alpha Select and Piper Jaffray Healthcare conferences presentations will be available online from the Investor Relations page of the Company's website at http://investors.caredxinc.com. The webcast replay of each presentation will be available on the Company's website for 90 days. Due to the one-on-one only format of the Mizuho and Evercore ISI MedTools conferences, no webcasts will be available.
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, diagnostic solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying risk of rejection in heart transplant recipients.
CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. For more information, please visit: www.CareDx.com.
CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. For more information, please visit: www.CareDx.com.
Investor Relations Contact Jamar Ismail, Vice President Westwicke Partners, LLC T: +1 415-513-1282 E: email@example.com